Servier
About Servier
Servier is a global pharmaceutical company focused on oncology and neurology, with research spanning cardiovascular diseases, cancers, diabetes, immune-inflammatory and neuropsychiatric diseases. The US arm communicates a commitment to science-driven therapeutics and patient care, supported by in-house research capabilities and a broad pipeline. It emphasizes partnerships, clinical development, and a patient-centric approach across its programs. Servier US highlights its leadership in oncology and neurology while addressing rare diseases and unmet medical needs.
Recent News
MoonLake Revives FDA Push; Biotech Trio to Debut in Hong Kong
Servier Signs €1bn-Plus AI Pact with Iktos
Insilico Medicine Welcomes Dr. Halle Zhang as New Vice President of Clinical Development for Oncology
Qualcomm Downgraded, Rivian Upgraded: Wall Street's Top Analyst Calls
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
IDEAYA and Servier’s Eye Cancer Drug Heads to FDA After Delivering ‘Best in Class’ Efficacy
Servier Launches VC Unit Focused on European Biotech Startups
More Cash Flows Into Biotechs During Conference Week: Finance Report
Top Biotech Deals in March 2026
kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
IDEAYA Biosciences Shows 58% Reduction in Disease Progression in Late‑Stage Uveal Melanoma Trial
Behind the Headlines Episode 32: AI’s Power, NVIDIA & Lilly, Revolution Medicine
Servier to Acquire Day One Biopharmaceuticals in a $2.5 Billion Cash Deal
Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time
A $2.5 Billion Commitment to Children with Cancer: Servier Acquires Day One Biopharmaceuticals
IDEAYA/Servier PKC Drug Aces Uveal Melanoma Trial
Insilico’s Latest Deal Is a $120M Cardiometabolic Drug Discovery Pact with Qilu Pharma
